CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to enhance cancer diagnosis by developing hybrid antibodies that allow for rapid radiolabeling directly at tumor sites. This innovative approach seeks to improve the visualization of tumors for better imaging results.
Diagnosing cancer as early as possible is one of the most powerful strategies in modern medicine to improvehuman well-being.
Antibodies (Abs) are excellent molecules that can be used to target specific tumors.
As Absrequire hours to days for accumulating on tumor surfaces, the use of Abs for nuclear imaging (such as PETimaging) is limited by the short half-lives of popular radioisotopes.
Therefore, we plan to move the step of radiolabelingfrom the bench to the tumor itself.
However, the entangle…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Mainz
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
